Cargando…

468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

Detalles Bibliográficos
Autores principales:	Dubberke, Erik, Orenstein, Robert, Mariani, Paul, Mullane, Kathleen, Sobcinski, Mary Kay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782012/ http://dx.doi.org/10.1093/ofid/ofu052.334

Ejemplares similares

1657 Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study
por: Orenstein, Robert, et al.
Publicado: (2014)

1799 Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antiobiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study
por: Mariani, Paul, et al.
Publicado: (2014)

The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660
por: Orenstein, Robert
Publicado: (2022)

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2022)

1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
por: Mische, Sarah, et al.
Publicado: (2018)

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
por: Orenstein, Robert, et al.
Publicado: (2022)

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
por: Feuerstadt, Paul, et al.
Publicado: (2022)

1039. Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection—Results from the PUNCH CD3 Phase 3 Trial
por: Papazyan, Romeo, et al.
Publicado: (2021)

669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection
por: Jones, Courtney, et al.
Publicado: (2019)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

1796 Recovery of Clostridium difficile, Vancomycin Resistant Enterococcus and Methicillin Resistant Staphylococcus aureus from the Food of Hospitalized Patients
por: Kwon, Jennie H., et al.
Publicado: (2014)

670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660
por: Hau, Heidi, et al.
Publicado: (2019)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial
por: Kwak, Suryang, et al.
Publicado: (2020)

Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
por: Khanna, Sahil, et al.
Publicado: (2022)

1658 C. difficile Recurrence is a Strong Predictor of 30-day Rehospitalization Among ICU Patients
por: Zilberberg, Marya D., et al.
Publicado: (2014)

1646 Evidence of hospital-associated Clostridium difficile transmission between patients with asymptomatic carriage and patients with Clostridium difficile infection
por: Galdys, Alison, et al.
Publicado: (2014)

113 Procedure-specific Surgical Site Infection (SSI) Prevalence Widely Varies within Certain NHSN (National Healthcare Safety Network) Surgery Groups
por: Saeed, Mohammed, et al.
Publicado: (2014)

Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile
por: Khanna, Sahil, et al.
Publicado: (2017)

29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection
por: Ferdyan, Nicky, et al.
Publicado: (2020)

1631 The Impact of Obesity of Clostidium difficile Recurrence
por: Lou, Uvette, et al.
Publicado: (2014)

1624 Risk Factors for Hospital-Acquired Clostridium difficile
por: Knepper, Bryan, et al.
Publicado: (2014)

525 Epidemiology and burden of recurrent Clostridium difficile infections
por: Sheitoyan-Pesant, Caroline, et al.
Publicado: (2014)

Microbiome Restoration by RBX2660 Does Not Preclude Recurrence of Multidrug-Resistant Urinary Tract Infection Following Subsequent Antibiotic Exposure: A Case Report
por: Keen, Eric C, et al.
Publicado: (2020)

71 Alterations in the Gut Microbiome in Recurrent Clostridium difficile Infection
por: Wang, Gary, et al.
Publicado: (2014)

1628 Accuracy of Healthcare Facility-Onset Clostridium difficile Classification
por: Trappler, Regan, et al.
Publicado: (2014)

1634 Clinical Characteristics of Relapses AND Reinfections in Clostridium difficile Infection
por: Kim, Jieun, et al.
Publicado: (2014)

1626 The relationship of Bristol Stool Scale to Clostridium difficile infection
por: Caroff, Daniel, et al.
Publicado: (2014)

1642 Identifying Targets for Prevention Through Clostridium difficile Population Surveillance
por: Dumyati, Ghinwa, et al.
Publicado: (2014)

1649 Acquisition of Clostridium difficile Associated with Potentially Contaminated Inpatient Rooms
por: Williams, Catherine, et al.
Publicado: (2014)

1673 Microbial and Inflammatory Markers for Fatal Clostridium difficile Associated Diarrhea
por: Jiang, Zhi-Dong, et al.
Publicado: (2014)

1620 Extraintestinal Clostridium difficile infections: A Single Center Experience
por: Gupta, Arjun, et al.
Publicado: (2014)

1644 Risk Factors for Community-Associated Clostridium difficile Infection in Children
por: Crews, Jonathan, et al.
Publicado: (2014)

1660 Risk of Recurrent Clostridium difficile Infection: Impact of Diagnostics and Treatment
por: Reddy, Sujan C., et al.
Publicado: (2014)

1798 Oral, Frozen Fecal Microbiota Capsules for Relapsing Clostridium difficile Infection
por: Youngster, Ilan, et al.
Publicado: (2014)

467 Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections
por: Flaherty, Sarah, et al.
Publicado: (2014)

893 Vancomycin Resistant Enterococcus (VRE) Rates in Ontario, Canada After the Discontinuation of VRE Screening and Control Practices by Some Hospitals: Interim Results
por: Lam, Freda, et al.
Publicado: (2014)

1641 Evaluation of Co-Infections among Patients with Community-Associated Clostridium difficile Infection
por: Cohen, Jessica, et al.
Publicado: (2014)

527 Age-Related Changes in the Incidence of Community-Associated Clostridium Difficile Infection (CDI)
por: Faden, Howard
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gtv0k82h74jk8a8d66touru9d5